LONG MINI-FUTURE - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 14:02:05 2024-06-28 EDT | ||
| 14.62 EUR | +1.25% |
|
| Current month | +17.81% | ||
| 1 month | +21.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 14.62 | +1.25% |
| 24-06-27 | 14.44 | +0.28% |
| 24-06-26 | 14.4 | +0.84% |
| 24-06-25 | 14.28 | -2.33% |
| 24-06-24 | 14.62 | +4.65% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 02:02 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GFH |
| ISIN | DE000VU8GFH2 |
| Date issued | 2023-06-13 |
| Strike | 320.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.54 € |
|---|---|
| Lowest since issue | 3.72 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
